Cargando…

Lentiviral gene therapy prevents anti-human acid α-glucosidase antibody formation in murine Pompe disease

Enzyme replacement therapy (ERT) is the current standard treatment for Pompe disease, a lysosomal storage disorder caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). ERT has shown to be lifesaving in patients with classic infantile Pompe disease. However, a major drawback is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Qiushi, Vlaar, Eva C., Catalano, Fabio, Pijnenburg, Joon M., Stok, Merel, van Helsdingen, Yvette, Vulto, Arnold G., Unger, Wendy W.J., van der Ploeg, Ans T., Pijnappel, W.W.M. Pim, van Til, Niek P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127119/ https://www.ncbi.nlm.nih.gov/pubmed/35662813 http://dx.doi.org/10.1016/j.omtm.2022.04.016

Ejemplares similares

IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy
por: Liang, Qiushi, et al.
Publicado: (2022)

Antisense Oligonucleotides Promote Exon Inclusion and Correct the Common c.-32-13T>G GAA Splicing Variant in Pompe Disease
por: van der Wal, Erik, et al.
Publicado: (2017)

Lentiviral Hematopoietic Stem Cell Gene Therapy Corrects Murine Pompe Disease
por: Stok, Merel, et al.
Publicado: (2020)

From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: a Pipeline for the Development of Antisense Oligonucleotides
por: Bergsma, Atze J, et al.
Publicado: (2016)

Extension of the Pompe mutation database by linking disease‐associated variants to clinical severity
por: Niño, Monica Y., et al.
Publicado: (2019)

Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease
por: Schaaf, Gerben J., et al.
Publicado: (2015)

Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease
por: van Kooten, Harmke A., et al.
Publicado: (2022)

GAA Deficiency in Pompe Disease Is Alleviated by Exon Inclusion in iPSC-Derived Skeletal Muscle Cells
por: van der Wal, Erik, et al.
Publicado: (2017)

A generic assay for the identification of splicing variants that induce nonsense-mediated decay in Pompe disease
por: Bergsma, Atze J., et al.
Publicado: (2020)

Tagged IDS causes efficient and engraftment-independent prevention of brain pathology during lentiviral gene therapy for Mucopolysaccharidosis type II
por: Catalano, Fabio, et al.
Publicado: (2023)

A genetic modifier of symptom onset in Pompe disease
por: Bergsma, Atze J., et al.
Publicado: (2019)

Sharpening the Molecular Scissors: Advances in Gene-Editing Technology
por: Broeders, Mike, et al.
Publicado: (2019)

Gene Therapy Developments for Pompe Disease
por: Unnisa, Zeenath, et al.
Publicado: (2022)

Broad variation in phenotypes for common GAA genotypes in Pompe disease
por: Niño, Monica Y., et al.
Publicado: (2021)

Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease
por: Ernst, Martijn P.T., et al.
Publicado: (2020)

Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience
por: Niño, Monica Y., et al.
Publicado: (2020)

Novel GAA Variants and Mosaicism in Pompe Disease Identified by Extended Analyses of Patients with an Incomplete DNA Diagnosis
por: in ’t Groen, Stijn L.M., et al.
Publicado: (2020)

Effects of exercise training in 23 adults with Pompe disease receiving enzyme therapy
por: van den Berg, Linda, et al.
Publicado: (2013)

Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease
por: Schaaf, Gerben J., et al.
Publicado: (2018)

Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
por: de Faria, Douglas O. S., et al.
Publicado: (2020)

Hearing in adults with Pompe disease
por: van der Beek, Nadine A. M. E., et al.
Publicado: (2011)

A conceptual disease model for adult Pompe disease
por: Kanters, Tim A., et al.
Publicado: (2015)

Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long‐term clinical outcome of classic infantile Pompe patients
por: Poelman, Esther, et al.
Publicado: (2020)

Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolism
por: Canibano‐Fraile, Rodrigo, et al.
Publicado: (2022)

Effects of immunomodulation in classic infantile Pompe patients with high antibody titers
por: Poelman, E., et al.
Publicado: (2019)

Newborn screening for Pompe disease in Italy: Long-term results and future challenges
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

A Generic Assay to Detect Aberrant ARSB Splicing and mRNA Degradation for the Molecular Diagnosis of MPS VI
por: Broeders, Mike, et al.
Publicado: (2020)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
por: Kanters, Tim A, et al.
Publicado: (2014)

Lentiviral gene transfer into human and murine hematopoietic stem cells: size matters
por: Canté-Barrett, Kirsten, et al.
Publicado: (2016)

Impact of enzyme replacement therapy on survival in adults with Pompe disease
por: Güngör, Deniz, et al.
Publicado: (2013)

The Pompe Registry: tracking Pompe disease symptoms in a broad patient population
por: Byrne, B, et al.
Publicado: (2008)

The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease
por: Kuperus, Esther, et al.
Publicado: (2018)

Newborn screening for pompe disease? a qualitative study exploring professional views
por: van El, Carla G, et al.
Publicado: (2014)

Enzyme replacement therapy and fatigue in adults with Pompe disease
por: Güngör, Deniz, et al.
Publicado: (2013)

Diffusion tensor imaging of the brain in Pompe disease
por: van den Dorpel, Jan J. A., et al.
Publicado: (2022)

Association of Muscle Strength and Walking Performance in Adult Patients With Pompe Disease
por: Favejee, Marein M, et al.
Publicado: (2018)

Quantification of Diaphragm Mechanics in Pompe Disease Using Dynamic 3D MRI
por: Mogalle, Katja, et al.
Publicado: (2016)

MRI changes in diaphragmatic motion and curvature in Pompe disease over time
por: Harlaar, Laurike, et al.
Publicado: (2022)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
por: Kanters, Tim A., et al.
Publicado: (2017)

Minutes of the European POmpe Consortium (EPOC) Meeting March 27 to 28, 2015, Munich, Germany
por: Schoser, Benedikt, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ejbrh4fdig5k8viumbt1bcrug6